Table 1 Baseline characteristics, imaging and biological data according to outcomes at Day 21 after admission for COVID-19
|  | Survivors | Death | (p) | CMU | ICU + Death | (p) |
|---|---|---|---|---|---|---|
|  | n = 61 (75%) | n = 20 (25%) | n = 41 (50.6%) | n = 40 (49.4%) | ||
Anthropometry | ||||||
 Age, years (IQR) | 65 (56–72) | 71 (67–78) | 0.02 | 66 (57–77) | 69 (59–73) | 0.99 |
 Male, n(%) | 44 (72) | 15 (75) | 0.8 | 27 (66) | 31 (77.5) | 0.32 |
 Weight (kg) | 79 (66–90) | 79 (69–89) | 0.73 | 76 (65–90) | 79 (69–89) | 0.46 |
 BMI (kg/m2) | 26 (24–31) | 28 (25–31) | 0.32 | 25.7 (22–31) | 27.3 (25–31) | 0.19 |
Cardiometabolic risk profile | ||||||
 Glycemia, mmol/l | 8.4 (6.9–10.8) | 10.6 (8.9–13.2) | 0.03 | 8.2 (6.8–10.3) | 9.9 (7.3–13.1) | 0.03 |
 Active smoking, n(%) | 6 (9.8) | 1 (6.7) | 0.69 | 4 (9.7) | 3 (7.5) | 0.83 |
 Hypertension, n(%) | 42 (68.8) | 19 (95) | 0.02 | 30 (73.1) | 31 (77.5) | 0.65 |
 Dyslipidemia, n(%) | 24 (55.7) | 17 (85) | 0.02 | 21 (51.2) | 30 (75) | 0.03 |
 Insulin therapy, n(%) | 24 (39.3) | 9 (45) | 0.65 | 17 (41.5) | 16 (40) | 0.89 |
Quantitative Imaging biomarkers | ||||||
 Cardiac adipose tissue (mL) | 216 (138–280) | 259 (215–337) | 0.007 | 183 (126–265) | 248 (200–340) | 0.005 |
 Cardiac adipose tissue (mL/m2) | 112 (72–150) | 148 (121–178) | 0.006 | 106 (72–144) | 138 (104–171) | 0.01 |
 Lung CT scan severity score |  |  | 0.22 |  |  | 0.08 |
 Minimal (10%) | 8 (12) | 5 (25) |  | 7 (17) | 6 (15) |  |
 Moderate (10–25%) | 18 (29) | 4 (20) |  | 15 (37) | 7 (17) |  |
 Extensive (25–50%) | 24 (40) | 10 (50) |  | 16 (39) | 17 (43) |  |
 Severe (> 50%) | 11 (19) | 1 (5) |  | 3 (7) | 10 (25) |  |
Inflammatory markers | ||||||
 Interleukin 6 (pg/mL) | 25 (10–41) | 56.3 (50.8–98.2) |  < 0.001 | 24.3 (8.5–42) | 49 (25–56) | 0.002 |
 C-reactive protein (mg/L) | 87 (38–137) | 67 (36–157) | 0.87 | 84.5 (37–120) | 89 (41–168) | 0.46 |
 Procalcitonin (μg/L) | 0.16 (0.09–0.26) | 0.3 (0.1–0.5) | 0.04 | 0.15 (0.1–0.32) | 0.2 (0.1–0.35) | 0.09 |
 Fibrinogen (g/L) | 6.5 (5.7–7.5) | 6.6 (5.3–7.7) | 0.94 | 6.4 (5–7) | 6.7 (5.6–7.7) | 0.29 |
 Leukocytes (× 109/L) | 6.4 (5–7.9) | 8.3 (6.1–8.9) | 0.02 | 6.3 (5–8) | 7.7 (5.6–9) | 0.06 |
 Lymphocytes (× 109/L) | 1.1 (0.8–1.4) | 0.94 (0.7–1.3) | 0.11 | 1.1 (0.9–1.5) | 0.94 (0.7–1.3) | 0.04 |
Other biomarkers | ||||||
 D-dimers (ng/mL) | 825 (545–1775) | 1405 (680–2430) | 0.10 | 715 (477–1513) | 1340 (718–2310) | 0.009 |
 T-Troponin (ng/L) | 13.4 (9.4–34.2) | 45.2 (29.1–89.5) | 0.001 | 14 (9–32) | 33 (12–51) | 0.007 |
 Platelets (× 109/L) | 220 (166–291) | 201 (161–219) | 0.06 | 220 (164–293) | 205 (177–269) | 0.4 |
 AST (UI/L) | 59 (29–67) | 52 (37–79) | 0.53 | 43 (28–67) | 49 (34–80) | 0.48 |
 ALT (UI/L) | 35 (22–62) | 31 (20–38) | 0.19 | 31 (20–59) | 35 (20–55) | 0.82 |
 eGFR (mL/min/1.73m2) | 72 (49–98) | 69 (47–77) | 0.22 | 72 (49–101) | 71.5 (47–88) | 0.60 |